Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators
Source: View publication →
In patients with clinical evidence of heart failure following an acute myocardial infarction, early treatment with the ACE inhibitor ramipril significantly reduced all-cause mortality by 27% compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The AIRE trial established that initiating ACE inhibition (ramipril) between days 3 and 10 post-myocardial infarction in patients exhibiting clinical signs of heart failure yields a substantial, rapid mortality benefit. The absolute risk reduction of approximately 6% translated to an impressive number-needed-to-treat (NNT) of roughly 17 to save one life over 15 months. Together with other landmark trials like SAVE and TRACE, AIRE provided definitive evidence for the routine use of ACE inhibitors to attenuate adverse cardiac remodeling and prevent death in high-risk post-MI patients.
Historical Context
By the early 1990s, reperfusion therapy (thrombolytics) and aspirin had improved post-MI survival, yet patients developing heart failure remained at a high risk for death. While the 1992 SAVE trial had just demonstrated the benefits of the ACE inhibitor captopril in patients with asymptomatic left ventricular dysfunction (ejection fraction ≤ 40%), it explicitly excluded patients with overt clinical heart failure. The AIRE trial was specifically designed to investigate the highest-risk subset—those who developed transient or persistent clinical heart failure post-MI. The overwhelming success of AIRE solidified ACE inhibitors as a foundational, life-saving therapy in the immediate post-MI setting for patients with pump failure.
Guided Discussion
High-yield insights from every perspective
What is the pathophysiological mechanism by which ramipril prevents mortality in patients who develop heart failure after an acute myocardial infarction?
Key Response
ACE inhibitors like ramipril prevent angiotensin II-mediated adverse cardiac remodeling, specifically ventricular dilation, hypertrophy, and fibrosis. They also decrease both preload and afterload, reducing myocardial oxygen demand and wall stress during the vulnerable post-infarction healing phase.
When initiating an ACE inhibitor like ramipril early in the post-MI period for a patient with signs of heart failure, what critical parameters must be monitored, and what are the main contraindications?
Key Response
Clinicians must monitor blood pressure for hypotension, renal function for acute kidney injury, and serum potassium for hyperkalemia. Contraindications include a history of angioedema, bilateral renal artery stenosis, and pregnancy. The AIRE trial demonstrated that early initiation (days 2-9) is safe and effective when these are closely monitored.
How did the AIRE trial's inclusion criteria fundamentally differ from the concurrent SAVE trial regarding post-MI patients, and how does this shape our understanding of ACE inhibitor benefits?
Key Response
The SAVE trial enrolled patients with asymptomatic left ventricular dysfunction (LVEF < 40%), whereas AIRE enrolled patients based purely on clinical evidence of heart failure, regardless of a specific echocardiographic ejection fraction cutoff. Together, they proved that neurohormonal blockade is critical across both clinical and subclinical spectrums of post-MI ventricular dysfunction.
Given the profound 27% mortality reduction seen in AIRE, how do we contextualize this historical finding when teaching the sequencing of modern guideline-directed medical therapy (GDMT) for post-MI heart failure today?
Key Response
While modern post-MI care includes early reperfusion, beta-blockers, MRAs, and SGLT2 inhibitors (and often ARNI instead of ACEi for chronic HFrEF), AIRE established the foundational principle of early RAAS blockade to halt remodeling. Attendings should highlight AIRE to emphasize why ACE inhibitors remain a crucial, cost-effective, and rapidly accessible first-line option in the critical early post-MI window.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The AIRE study demonstrated a significant mortality benefit with the Kaplan-Meier survival curves separating very early. How does this early divergence influence statistical assumptions and sample size calculations for contemporary post-MI event-driven trials?
Key Response
Early separation indicates the treatment addresses an acute, high-risk vulnerability window. Trialists must account for non-proportional hazards where the treatment effect is concentrated early. This necessitates adequate statistical power in the first 30-90 days and utilizes time-to-first-event survival analyses to accurately capture the peak relative risk reduction without dilution from long-term follow-up.
A critical reviewer evaluating AIRE by contemporary standards might flag the background medical therapy. What specific gaps in concurrent treatments exist in the AIRE cohort, and how does this threaten the modern generalizability of its absolute risk reduction?
Key Response
Background therapy in the early 1990s AIRE cohort lacked modern rates of primary PCI, high-intensity statins, dual antiplatelet therapy, and early beta-blocker utilization. A critical editor would note that while the relative biological mechanism of RAAS blockade remains valid, the absolute risk reduction observed in AIRE would likely be significantly attenuated in a modern, optimally revascularized cohort.
Based on the foundational findings of the AIRE trial, how do current AHA/ACC/HFSA guidelines classify the use of ACE inhibitors in post-MI patients, and what specific clinical triggers mandate their initiation?
Key Response
Current guidelines provide a Class 1 (Level of Evidence A) recommendation for ACE inhibitors in post-MI patients. The AIRE trial specifically supports the trigger of 'clinical heart failure', alongside other triggers like anterior MI location or LVEF <= 40 percent. The guidelines state these patients should be started on an ACE inhibitor before hospital discharge and continued indefinitely to reduce mortality and prevent progression of heart failure.
Clinical Landscape
Noteworthy Related Trials
SAVE Trial
Tested
Captopril 50mg TID
Population
Post-MI patients with LVEF <= 40% without overt HF
Comparator
Placebo
Endpoint
All-cause mortality
TRACE Trial
Tested
Trandolapril up to 4mg daily
Population
Post-MI patients with LVEF <= 35%
Comparator
Placebo
Endpoint
All-cause mortality
VALIANT Trial
Tested
Valsartan, captopril, or combination
Population
Post-MI patients with heart failure or LV dysfunction
Comparator
Captopril alone
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis